Topics

J&J seeks expanded label indication for antidepressant Spravato

05:51 EDT 4 Oct 2019 | SmartBrief

An application was filed by Johnson & Johnson seeking the FDA's approval regarding a new claim on its label for its antidepre -More

Original Article: J&J seeks expanded label indication for antidepressant Spravato

NEXT ARTICLE

More From BioPortfolio on "J&J seeks expanded label indication for antidepressant Spravato"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...